Weight loss shots like Wegovy and Zepbound are covered by some insurance plans, but coverage is far from universal and often comes with strict requirements. Whether you can get these medications paid for depends on your type of insurance, your BMI, any related health conditions, and sometimes your employer’s specific benefit choices. Most people will need to navigate prior authorization, and many will face an initial denial.
What Private Insurance Typically Requires
Private insurers that do cover weight loss shots generally follow a standard set of criteria. You’ll need a BMI of 30 or higher, or a BMI of 27 or higher combined with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or impaired glucose tolerance. These thresholds mirror the FDA-approved labeling for the drugs themselves.
Even when you meet the clinical criteria, your insurer will almost certainly require prior authorization before approving the prescription. This means your doctor submits documentation proving you qualify, and the insurance company reviews it before agreeing to pay. Some plans also require evidence that you’ve tried other weight loss methods first, such as a supervised diet program or older, less expensive medications. The prior authorization process can take days to weeks, and denials are common on the first attempt.
The bigger issue is that many private plans simply exclude weight loss medications altogether. The Affordable Care Act requires insurers to cover obesity screening and behavioral counseling, but it does not mandate coverage for weight loss drugs. This gives insurers wide latitude to decline coverage, and many take that option.
How Many Employers Actually Cover These Drugs
Employer-sponsored plans vary enormously. A 2025 survey published in Health Affairs found that only about 19 percent of large firms covering health benefits included GLP-1 medications for weight loss. Coverage was more common at the biggest companies: 43 percent of firms with 5,000 or more employees covered these drugs in 2025, up from 28 percent the year before.
That trend is moving in the right direction, but it still means the majority of workers at large companies, and an even larger share at smaller firms, don’t have this benefit. If your employer doesn’t include weight loss medications in the plan, your doctor can still prescribe the drug, but you’d pay the full list price, which typically runs over $1,000 per month. Some employers are adding coverage with conditions attached, like requiring participation in a weight management program alongside the medication.
Medicare Coverage Is Expanding, With Limits
Medicare has historically excluded weight loss drugs from Part D coverage. That started to change in 2024 when Wegovy received FDA approval specifically to reduce the risk of major cardiovascular events in adults with established heart disease who also have obesity or are overweight. At that point, Medicare Part D began covering Wegovy for that narrow combination of conditions, not for weight loss alone.
A much broader expansion launches on July 1, 2026. CMS is running a pilot program called the Medicare GLP-1 Bridge, which will cover Wegovy (both injection and tablets), Zepbound, and a newer drug called Foundayo for weight loss through December 31, 2027. To qualify, your doctor must submit a prior authorization confirming you meet one of three tiers of eligibility:
- BMI of 35 or higher with no additional conditions required
- BMI of 30 or higher plus a diagnosis of heart failure with preserved ejection fraction, uncontrolled high blood pressure (despite already taking two blood pressure medications), or stage 3a or higher chronic kidney disease
- BMI of 27 or higher plus a diagnosis of pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease
Your prescription must also include a structured nutrition and physical activity plan consistent with the drug’s FDA label. If you already qualify for coverage under the standard Part D benefit (for example, Wegovy for cardiovascular risk reduction or Zepbound for obstructive sleep apnea), you wouldn’t use the Bridge program. You’d go through your plan’s regular formulary process instead.
Why Ozempic Is a Different Story
Ozempic contains the same active ingredient as Wegovy but is FDA-approved only for type 2 diabetes, not weight loss. When doctors prescribe Ozempic off-label for weight management, insurers routinely deny coverage. They point to the fact that the drug isn’t approved for that use, and because no federal law requires coverage of obesity medications, they’re on solid legal ground to refuse.
Some insurers have also cited concerns about long-term effectiveness, noting that weight tends to return when the medication is stopped. If you have type 2 diabetes, Ozempic is generally covered under your plan’s diabetes benefit. But if weight loss is the primary goal and you don’t have a diabetes diagnosis, expect a denial. The same logic applies to Mounjaro, which is the diabetes-approved version of tirzepatide. Its weight loss counterpart, Zepbound, is the one with FDA approval for obesity.
Medicaid Coverage Varies by State
Medicaid programs are managed at the state level, and coverage for weight loss medications is inconsistent. Some states have added GLP-1 drugs to their preferred drug lists, while others exclude them entirely or restrict access to patients with diabetes only. If you’re on Medicaid, your best starting point is checking your state’s formulary or calling your managed care plan directly. Coverage rules can change year to year as states renegotiate drug pricing.
What to Do If You’re Denied
A denial isn’t necessarily the final answer. Most insurance plans have a formal appeals process, and many initial denials are overturned when additional documentation is provided. Your doctor can submit a letter of medical necessity explaining why the medication is appropriate for your specific health situation, including any failed attempts at other weight loss methods and any obesity-related conditions you have.
If your plan excludes weight loss drugs entirely, an appeal on medical grounds is unlikely to succeed because the exclusion applies regardless of your individual circumstances. In that case, you have a few other options. Manufacturer savings programs exist for both Wegovy and Zepbound, though they’re primarily designed for people who have commercial insurance that covers the drug but leaves a high copay. If your plan doesn’t cover the medication at all, manufacturer coupons may not apply.
Some compounding pharmacies offer versions of semaglutide at lower prices, though the FDA has raised safety concerns about compounded GLP-1 drugs. Telehealth weight loss clinics sometimes negotiate lower cash prices or offer payment plans, but you’re still looking at hundreds of dollars per month out of pocket. For many people, the most practical path is asking your HR department whether your employer plan covers these medications, or whether coverage might be added during the next open enrollment cycle.